Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

Seung Tae Lee, Joon Ho Jang, June Won Cheong, Jin Seok Kim, Ho Young Maemg, Jee Sook Hahn, Yun Woong Ko, Yoo Hong Min

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.

Original languageEnglish
Pages (from-to)1128-1131
Number of pages4
JournalBritish Journal of Haematology
Volume118
Issue number4
DOIs
Publication statusPublished - 2002 Sep 25

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype'. Together they form a unique fingerprint.

  • Cite this